TEVA
insider transactionsTEVA PHARMACEUTICAL INDUSTRIES LTD — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-529.9K
0 buy · 529.9K sell
Net value · 90d
-$18.6M
$0 in · $18.6M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
10
0 buy · 529.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
EVP, Chief Financial Officer · 10b5-1
$3.6M
106.6K sh · $34.10
Own -62%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +25%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +15%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +14%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +14%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +302%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +13%
-
Exercise·M
President and CEO · 10b5-1
$0
13.0K sh
Own +50%
-
Sell·S
President and CEO · 10b5-1
$211.4K
6.2K sh · $34.35
Own -1%
-
Exercise·M
President and CEO · 10b5-1
—
13.0K sh
Own +1%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +1%
-
Exercise·M
Director
$0
14.5K sh
Own New
-
Exercise·M
Director
—
14.5K sh
Own +13%
-
Exercise·M
Director
$0
21.7K sh
Own New
-
Exercise·M
Director
—
21.7K sh
Own +5%
-
Exercise·M
EVP, Global Operations · 10b5-1
$0
16.2K sh
Own +100%
-
Sell·S
EVP, Global Operations · 10b5-1
$532.3K
16.2K sh · $32.87
Own -62%
-
Exercise·M
EVP, Global Operations · 10b5-1
—
16.2K sh
Own +162%
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
7.2K sh
Own New
-
Grant·A
Director
$0
10.9K sh
Own New
-
Exercise·M
EVP, Business Development · 10b5-1
$0
74.0K sh
Own New
-
Exercise·M
EVP, Business Development · 10b5-1
$0
11.8K sh
Own +50%
-
Sell·S
EVP, Business Development · 10b5-1
$1.3M
35.9K sh · $35.58
Own -45%
-
Exercise·M
EVP, Business Development · 10b5-1
—
74.0K sh
Own +1214%
-
Sell·S
EVP, Business Development · 10b5-1
$204.5K
5.7K sh · $35.58
Own -49%
-
Exercise·M
EVP, Business Development · 10b5-1
—
11.8K sh
Own New
-
Sell·S
EVP, Chief Financial Officer · 10b5-1
$5.5M
153.3K sh · $35.61
Own -47%
-
Sell·S
Chief Accounting Officer
$384.4K
10.7K sh · $36.00
Own -35%
-
Sell·S
EVP, Europe Commercial
$1.1M
30.0K sh · $35.40
Own -35%
-
Sell·S
See "Remarks"
$5.0M
144.2K sh · $34.99
Own -64%
-
Sell·S
EVP, U.S. Commercial
$750.6K
21.3K sh · $35.31
Own -25%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Eliyahu Sharon Kalif KEY 10b5-1 | Sell S | 106.6K | $3.6M |
| Jun 5, 2026 | Tal Zvi Zaks | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Tal Zvi Zaks | Exercise M | 14.5K | — |
| Jun 5, 2026 | Ronit Satchi-Fainaro | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Ronit Satchi-Fainaro | Exercise M | 14.5K | — |
| Jun 5, 2026 | Perry Nisen | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Perry Nisen | Exercise M | 14.5K | — |
| Jun 5, 2026 | Roberto Mignone | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Roberto Mignone | Exercise M | 14.5K | — |
| Jun 5, 2026 | Chen Lichtenstein | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Chen Lichtenstein | Exercise M | 14.5K | — |
| Jun 5, 2026 | Gerald M Lieberman | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Gerald M Lieberman | Exercise M | 14.5K | — |
| Jun 5, 2026 | Richard D Francis KEY 10b5-1 | Exercise M | 13.0K | $0 |
| Jun 5, 2026 | Richard D Francis KEY 10b5-1 | Sell S | 6.2K | $211.4K |
| Jun 5, 2026 | Richard D Francis KEY 10b5-1 | Exercise M | 13.0K | — |
| Jun 5, 2026 | Amir Elstein | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Amir Elstein | Exercise M | 14.5K | — |
| Jun 5, 2026 | Rosemary A Crane | Exercise M | 14.5K | $0 |
| Jun 5, 2026 | Rosemary A Crane | Exercise M | 14.5K | — |
| Jun 5, 2026 | Sol J Barer | Exercise M | 21.7K | $0 |
| Jun 5, 2026 | Sol J Barer | Exercise M | 21.7K | — |
| Jun 3, 2026 | Matthew Shields 10b5-1 | Exercise M | 16.2K | $0 |
| Jun 3, 2026 | Matthew Shields 10b5-1 | Sell S | 16.2K | $532.3K |
| Jun 3, 2026 | Matthew Shields 10b5-1 | Exercise M | 16.2K | — |
| May 28, 2026 | Tal Zvi Zaks | Grant A | 7.2K | $0 |
| May 28, 2026 | Ronit Satchi-Fainaro | Grant A | 7.2K | $0 |
| May 28, 2026 | Perry Nisen | Grant A | 7.2K | $0 |
| May 28, 2026 | Roberto Mignone | Grant A | 7.2K | $0 |
| May 28, 2026 | Chen Lichtenstein | Grant A | 7.2K | $0 |
| May 28, 2026 | Gerald M Lieberman | Grant A | 7.2K | $0 |
| May 28, 2026 | Amir Elstein | Grant A | 7.2K | $0 |
| May 28, 2026 | Rosemary A Crane | Grant A | 7.2K | $0 |
| May 28, 2026 | Sol J Barer | Grant A | 10.9K | $0 |
| May 14, 2026 | Evan Lippman 10b5-1 | Exercise M | 74.0K | $0 |
| May 14, 2026 | Evan Lippman 10b5-1 | Exercise M | 11.8K | $0 |
| May 14, 2026 | Evan Lippman 10b5-1 | Sell S | 35.9K | $1.3M |
| May 14, 2026 | Evan Lippman 10b5-1 | Exercise M | 74.0K | — |
| May 14, 2026 | Evan Lippman 10b5-1 | Sell S | 5.7K | $204.5K |
| May 14, 2026 | Evan Lippman 10b5-1 | Exercise M | 11.8K | — |
| May 14, 2026 | Eliyahu Sharon Kalif KEY 10b5-1 | Sell S | 153.3K | $5.5M |
| May 6, 2026 | Amir Weiss | Sell S | 10.7K | $384.4K |
| May 5, 2026 | Richard Daniell | Sell S | 30.0K | $1.1M |
| May 1, 2026 | Mark Sabag | Sell S | 144.2K | $5.0M |
| Apr 30, 2026 | Christine Fox | Sell S | 21.3K | $750.6K |
About TEVA insider trading
This page tracks insider transactions for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.